Biochemical markers of bone turnover in osteonecrosis of the jaw in patients with osteoporosis and advanced cancer involving the bone

Annals of the New York Academy of Sciences

Volumn 1218, Issue 1, 2011, Pages 80-87

  Cremers, Serge ^a   Farooki, Azeez ^b  

^a Columbia University ^*  (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Biochemical markers of bone turnover; Bisphosphonates; Bone turnover markers; ONJ; Osteonecrosis of the jaw

Indexed keywords

ALENDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADVANCED CANCER; ARTICLE; BONE CANCER; BONE TURNOVER; CONVALESCENCE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; JAW OSTEONECROSIS; OSTEOPOROSIS; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN DEGRADATION; RISK FACTOR; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79551560562     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05770.x     Document Type: Article

References (32)

1. Khosla, S. et al 2007. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 22: 1479-1491.
2. Bilezikian, J.P. 2006. Osteonecrosis of the jaw-do bisphosphonates pose a risk? N. Engl. J. Med. 355: 2278-2281.
3. Durie, B.G.M., M. Katz & J. Crowley 2005. Osteonecrosis of the jaw and BPs. N. Engl. J. Med. 353: 99-102.
4. Maerevoet, M., C. Martin & L. Duck 2005 Osteonecrosis of the jaw and bisphosphonates. N. Engl. J. Med. 353: 99-102.
5. Mavrokokki, T. 2007. Nature and frequency of BP-associated osteonecrosis of the jaws in Australia. J. Oral Maxillofac. Surg. 65: 415-423.
6. Dixon, R.B., N.D. Tricker & L.P. Garetto 1997. Bone turnover in elderly canine mandibles and tibia. J. Dent. Res. 76(IADR Abstracts): 2579.
7. Ashcroft, J. 2006. Bisphosphonates and phossy-jaw: breathing new life into an old problem. Lancet Oncol 7: 447-449.
8. Estilo, C.L., M. Fornier, A. Farooki, et al 2008. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 26: 4037-4038.
9. Brixen, & Eriksen 2006. Validation of biochemical markers of bone turnover. In pages 583-592 of Dynamics of Bone and Cartilage Metabolism. M.J. Seibel, S.P. Robins & J.P. Bilezikian, Eds. Academic Press. San Diego.
10. Seibel, M.J., R. Eastell, C.M. Grundberg, et al 2002 Biochemical markers of bone metabolism. In pages 1543-1572 of Principles of Bone Biology. 2nd ed. J.P. Bilezikian, L.G. Raisz & G.A. Rodan, Eds. Academic Press. San Diego.
11. Seibel, M. 2005. Biochemical markers of bone turnover. Part 1: biochemistry and variability. Clin. Biochem. Rev. 26: 97-122.
12. Hannon, R. & R Eastell 2000. Preanalyical variability of biochemical markers of bone turnover. Osteoporos. Int. 11 (Suppl. 6): S30-S44.
13. Ju, H.S., S. Leung, B. Brown, et al 1997. Comparison of analytical performance and biological variability of three bone resorption assays. Clin. Chem. 43: 1570-1576.
14. Okabe, R., K. Nakatsuka, M. Inaba, et al 2001 Clinical evaluation of the elecsys ß-crosslaps serum assay, a new assay for degradation products of type I collagen C-telopeptides. Clin. Chem. 47: 1410-1414.
15. Body, J.J. 2006. Metastatic bone disease. In pages 793-806 of Dynamics of Bone and Cartilage Metabolism: M.J. Seibel, S.P. Robins & J.P. Bilezikian, Eds. Academic Press. San Diego.
16. Cremers, S., P. Garnero 2006. Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls. Drugs 66: 2031-2058.
17. Papapoulos, S.E. 1995. Pharmacodynamics of bisphosphonates in man; implications for treatment. In pages 231-243 of Bisphosphonates on Bones. O. Bijvoet, H.A. Fleisch, R.E. Canfield & G. Russell, Eds. Elsevier. Amsterdam.
18. Bone, H.G. et al 2004. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 350: 1189-1199.
19. Watts, N.B., A. Chines, W.P. Olszynski, et al 2008. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos. Int. 19: 365-372.
20. Black, D.M., A.V. Schwartz, K.E. Ensrud et al 2006. Effects of continuing or stopping alendronate after 5 years of treatment" the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296: 2927-2938.
21. Lipton, A., R.J. Cook, P. Major, et al 2007. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 12: 1035-1043.
22. Coleman, R.E., P. Major, A. Lipton, et al 2005. The predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J. Clin. Oncol. 23: 4925-4935.
23. Rosen, L.S. et al 2004. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors. Cancer 100: 2613-2621.
24. Park, S., D. Borderie & C. Cormier 2007. Effect of spacing intravenous bisphosphonates in patients with multiple myeloma in plateau phase. Leukemia 21: 1596-1599.
25. Marx, R.E., J.E. Cillo, J.J. Ulloa 2007. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention and treatment. J. Oral. Maxillofac. Surg. 65: 2397-2410.
26. Hansen, T. et al 2006. Osteonecrosis of the jaws in patients treated with bisphosphonates-histomorphologic analysis in comparison with infected osteoradionecrosis. J. Oral Pathol. Med. 35: 155-160.
27. Grbic, J., D. Black, K. Lyles, et al 2008. Osteonecrosis of the jaw: zoledronic acid 5 mg experience in a variety of osteoporosis indications. J. Bone Miner. Res. 23: S69.
28. Black, D.M., P.D. Delmas, R. Eastell, et al 2007. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356: 1809-1822.
29. Lee, C.Y.S., J.B. Suzuki 2010. CTX biochemical marker of bone metabolism. is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study. Implant. Dent. 19: 29-38.
30. Farooki, A., M. Fornier, S.C. Cremers, et al 2007 Abstract: bone turnover markers in cancer patients who developed ONJ while on intravenous bisphosphonates. Skeletal Complications of Malignancy V, Philadelphia, PA.
31. Don-Wauchope, A.C. & D.E. Cole 2009. The (mis) use of bone resorption markers in the context of bisphosphonate exposure, dental surgery and osteonecrosis of the jaw. Clin. Biochem. 42: 1194-1196.
32. Baim, S., P.D. Miller 2009. Perspective: assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J. Bone Miner. Res. 24: 561-574.